<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594370</url>
  </required_header>
  <id_info>
    <org_study_id>201803133RINC</org_study_id>
    <nct_id>NCT03594370</nct_id>
  </id_info>
  <brief_title>Multiple Noninvasive Examination Modality to Evaluate the Severity of Ocular Surface Disorders</brief_title>
  <official_title>Multiple Noninvasive Examination Modality to Evaluate the Severity of Ocular Surface Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Here the investigators proposed this study to collect cases of different etiologies of ocular&#xD;
      surface diseases. With at least one of these four non-invasive examination modalities, the&#xD;
      investigators aim to analyze and compare the detecting results. The investigators especially&#xD;
      focus on the possibility of using OCT to predict the condition of limbal epithelial stem&#xD;
      cells, aiming to use this patient-friendly tool to detect the patient's limbal conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In vivo confocal microscopy, anterior segment optical coherence tomography, keratograph and&#xD;
      impression cytology are noninvasive, rapid and easily repeatable technique to investigate&#xD;
      ocular surface disorders. In vivo confocal microscopy (IVCM) enables morphological and&#xD;
      quantitative analysis of ocular surface microstructure. Optical coherence tomography (OCT)&#xD;
      allows for imaging of the morphology of biological tissue with micrometer scale resolution at&#xD;
      imaging depths of 1 to 2mm below the tissue surface. [1,2] Anterior segment OCT (ASOCT) has&#xD;
      been developed to evaluate corneal diseases[3-8] in different layers. Keratography includes&#xD;
      noninvasive meibography and tear interferometry. The former demonstrates the morphology of&#xD;
      meibomian glands whereas the later observes quality and quantity of the lipid layer of the&#xD;
      tear film. Impression cytology shows the morphology of the corneal and conjunctival&#xD;
      epithelial cells, their staining behavior, and nuclear/cytoplasmic ratio could be observed in&#xD;
      detail.&#xD;
&#xD;
      Here the investigators proposed this clinical trial to collect cases of different etiologies&#xD;
      of ocular surface diseases. With at least one of these four non-invasive examination&#xD;
      modalities, the investigators aim to analyze and compare the detecting results. The&#xD;
      investigators especially focus on the possibility of using ASOCT to predict the condition of&#xD;
      limbal epithelial stem cells, aiming to use this patient-friendly tool to detect the&#xD;
      patient's limbal conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2018</start_date>
  <completion_date type="Actual">May 22, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>limbal structural abnormality</measure>
    <time_frame>assess the OCT limbal image at the baseline</time_frame>
    <description>atypical pattern of limbal Palisade of Vogt detected by OCT comparing to normal subjects</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Limbal Stem-cell Deficiency</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>Limbal image by OCT in normal subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advancing wave-like epitheliopathy</arm_group_label>
    <description>Limbal image by OCT in subjects with advancing wave-like epitheliopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocular rosacea or phlyctenulosis</arm_group_label>
    <description>Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Impression cytology(IC) is a technique which permits the retrieval of the outermost layer of&#xD;
      ocular surface cells via the use of various types of filters. It is a minimally invasive&#xD;
      method of evaluating human conjunctival epithelial cell morphology. IC may also be utilized&#xD;
      in the diagnosis of other ocular diseases, such as ocular surface squamous neoplasia, ocular&#xD;
      surface infections, keratoconus and thyroid orbitopathy. IC improves our understanding of the&#xD;
      pathophysiology of ocular surface disease, and provide biomarkers to be used as outcome&#xD;
      measures in clinical trials.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Our study is an institutional observation study recruits otherwise healthy patients aging&#xD;
        over 5 years old.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who is able to understand and cooperate with the examination: aged over 5&#xD;
             years.&#xD;
&#xD;
          -  Patient or the legal representative is able to read and sign an informed consent form.&#xD;
&#xD;
          -  Patient with one of the diagnosis listed below:&#xD;
&#xD;
               1. limbal insufficiency&#xD;
&#xD;
               2. phlyctenulosis&#xD;
&#xD;
               3. ocular rosacea&#xD;
&#xD;
               4. ocular graft-versus-host disease (GVHD)&#xD;
&#xD;
               5. dry eye syndrome (both aqueous deficiency or increased evaporative forms of dry&#xD;
                  eyes)&#xD;
&#xD;
               6. other ocular surface diseases (advancing wave-like epitheliopathy, long term use&#xD;
                  of anti-glaucoma eye drops)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients who decline to receive any of the non-invasive examinations mentions in this&#xD;
             clinical trial.&#xD;
&#xD;
          -  Patients younger than 5 years old.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-Li Chen</last_name>
    <role>Study Director</role>
    <affiliation>NTUH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NTUH</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

